June 2013
Volume 54, Issue 15
Free
ARVO Annual Meeting Abstract  |   June 2013
German Health Services Research Study: Estimated Prevalence and Incidence of Pathologic Myopia and Lack of Classification of different Stages of Pathologic Myopia
Author Affiliations & Notes
  • Marc Schargus
    Department of Ophthalmology, Univiversity Hospital, Wuerzburg, Germany
  • Daniel Pauleikhoff
    Eye Department, St. Francis Hospital, Muenster, Germany
  • Gisela Haeusser-Fruh
    Clinical Research, Novartis Pharma, Nuermberg, Germany
  • Mathias Maier
    Klinikum rechts der Isar Department and Polyclinic of Ophthalmology, Technical University Munich, Munich, Germany
  • Footnotes
    Commercial Relationships Marc Schargus, None; Daniel Pauleikhoff, None; Gisela Haeusser-Fruh, Novartis Pharma (E); Mathias Maier, None
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science June 2013, Vol.54, 1559. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to Subscribers Only
      Sign In or Create an Account ×
    • Get Citation

      Marc Schargus, Daniel Pauleikhoff, Gisela Haeusser-Fruh, Mathias Maier; German Health Services Research Study: Estimated Prevalence and Incidence of Pathologic Myopia and Lack of Classification of different Stages of Pathologic Myopia. Invest. Ophthalmol. Vis. Sci. 2013;54(15):1559.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: Currently, there are no data available in Germany on prevalence, incidence and treatment of pathologic myopia (PM)/high myopia and its complications. Additionally, there are different definitions of PM and its classification of severity and complications in the literature. Hence, the purpose of this study was to estimate the number of patients with different severity stages of PM in a clearly categorized scheme.

Methods: Health services survey with randomly selected ophthalmologists throughout Germany. Physicians were asked about diagnosis, monitoring of PM and health care situation. They were further asked to categorize myopic eyes into: 1. PM without macular degeneration (MD) and choroidal neovascularisation (CNV), 2. PM with MD and without CNV, or 3. CNV secondary to PM. Calculated prevalence/incidence were based on the number of patients reported by the participating ophthalmologists.

Results: 340 ophthalmologists took part (84.4% practice-based ophthalmologists, 11.8% retina specialists, 2.6% others) This reflects the real distribution of ophthalmologists throughout Germany. Overall patient number throughout these ophthalmologists was estimated at 2,146.398 patients per year. Based on the total number of patients per year and practice, the estimated prevalence of patients with myopia was calculated at 26.5% and with high myopia (>6D) at 3.4%. Of those, the prevalence/incidence of patients with PM (without MD and CNV) was calculated at 1.9%/0.6%, with PM and MD at 0.6%/0.2%, and with CNV secondary to PM at 0.2%/0.08%. The vast majority of physicians (93%) cited anti-VEGF injection as their most preferred treatment option for patients with CNV secondary to PM.

Conclusions: Estimated patient numbers were much higher than expected and varied considerably between physicians. This may be explained by double counting of patients by the different physicians to which patients had been referred to, the unequal grades of physician specialisation as well as by possibly underlying uncertainties regarding definitions, nomenclature and staging of PM/high myopia. Harmonised definitions, recommendation on diagnosis, disease information and continuous training on PM are required, as well as detailed epidemiological data from other countries for international comparisons.

Keywords: 453 choroid: neovascularization • 463 clinical (human) or epidemiologic studies: prevalence/incidence • 605 myopia  
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×